Navigation Links
Anadys Pharmaceuticals Announces Positive Results for ANA598 in Animal Model of Chronic Hepatitis C Virus Infection
Date:1/3/2008

dies further support continued development of ANA598 as a candidate for use in combination with other agents for the treatment of chronic HCV infection."

In June 2007, Anadys announced the nomination of ANA598 as a clinical development candidate. The selection of ANA598 represented the culmination of a comprehensive structure-based drug design program directed towards NS5B. ANA598 was selected based on an optimized balance of preclinical properties, including intrinsic potency as an NS5B inhibitor, cellular activity in the replicon assay, oral bioavailability and early indicators of safety and tolerability. ANA598 is a low-nanomolar inhibitor of HCV genotype 1a and 1b replicons. It exhibits good in vitro metabolic stability properties and does not significantly inhibit or induce cytochrome P450 enzymes. In vivo, ANA598 was well tolerated in 14-day dose range finding (DRF) animal toxicology studies. At doses corresponding to estimated human doses, 24 hour trough plasma concentrations of ANA598 exceeded the EC95 for HCV genotype 1a and 1b replicon inhibition. The EC95 is the concentration required in vitro to suppress hepatitis C viral RNA levels by 95% in the replicon assay.

ANA598 is currently completing IND enabling activities and an IND submission is targeted for the second quarter of 2008. "After completing the necessary IND enabling studies, we look forward to exploring the potential clinical utility of ANA598," said James Freddo, MD, Anadys' Chief Medical Officer. "Based on the in vitro and in vivo potency, pharmacokinetic and preliminary toxicologic properties of ANA598 demonstrated to date, we believe that this is an exciting new direct antiviral to investigate for the treatment of patients with hepatitis C virus infection."

About Anadys

Anadys Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to improving patient care by developing novel medicines in the areas of hepatitis C and oncology. The Company is developing ANA
'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
2. QuatRx Pharmaceuticals Announces Positive Phase 3 Results for Study of Ophena(TM) (ospemifene) to Treat Postmenopausal Vaginal Syndrome
3. Alseres Pharmaceuticals Initiates the ALTROPANE(R) POET-2 Phase III Clinical Trial Program
4. Solvay Pharmaceuticals, Inc. Responds to Advisory Committee Recommendation for Further Study of Tedisamil to Treat Atrial Fibrillation
5. XTL Biopharmaceuticals Presents Data Regarding its Hepatitis C Virus Small Molecule Program at Hep Dart 2007 - an International Scientific Conference on Viral Hepatitis
6. Celator(R) Pharmaceuticals Reports CPX-351 Shows Anti-Cancer Activity in Leukemia Patients
7. Keryx Biopharmaceuticals, Inc. Announces Phase 1 and Phase 2 Data on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Multiple Myeloma at 49th Annual Meeting of American Society of Hematology
8. Access Pharmaceuticals Demonstrates Ability to Significantly Reduce Glucose Levels in Pre-clinical Testing of Cobalamin(TM) Oral Insulin
9. Vion Pharmaceuticals To Present Preliminary Data on its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) at the American Society of Hematology Meeting
10. Vion Pharmaceuticals Announces Initiation of Clinical Trial of Cloretazine(R) (VNP40101M) in Combination with Stem Cell Transplantation
11. Sunesis Pharmaceuticals to Present Data on Two Product Candidates at the 49th Annual Meeting of the American Society of Hematology

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/30/2009)... N.J., Nov. 30 MedQuist ...ology-enabled clinical documentation services, tod...Nuance Communications, Inc. (Nuance) under which M...ch recognition engine and processing software for ... front-end speech recognition application for all ...
(Date:11/30/2009)...YORK, Nov. 30 Reportlinker.com ann...ble in its catalogue: ,, Diabetes Diagnostics ...eportlinker.com/p0164347/Diabetes-Diagnostics---A-...agnosis market is driven by a steady increase in t...in the developed and developing parts of the world...
(Date:11/30/2009).... 30 Dr. Jocelyn Rapelyea, Associa...George Washington University Medical Center in Was...ntified with Breast-Specific Gamma Imaging (BSGI) ...for needle biopsy as well, as for pre-operative lo...ological Society of North America (RSNA). ,, BS...
Breaking Medicine Technology:MedQuist Signs Agreement Extending Use of Real-Time Speech Recognition Engine to Wide Range of Medical Specialties 2Reportlinker Adds Diabetes Diagnostics - A Global Market Perspective 2Reportlinker Adds Diabetes Diagnostics - A Global Market Perspective 3Reportlinker Adds Diabetes Diagnostics - A Global Market Perspective 4Reportlinker Adds Diabetes Diagnostics - A Global Market Perspective 5Reportlinker Adds Diabetes Diagnostics - A Global Market Perspective 6Reportlinker Adds Diabetes Diagnostics - A Global Market Perspective 7Reportlinker Adds Diabetes Diagnostics - A Global Market Perspective 8Reportlinker Adds Diabetes Diagnostics - A Global Market Perspective 9Breast-Specific Gamma Imaging Identifies Occult Lesions Using Multi-Modality Imaging for Biopsy 2Disability Rates Continue Steady Climb According to CDAs 2008 Disability Claims Review 56752 1Disability Rates Continue Steady Climb According to CDAs 2008 Disability Claims Review 56752 2Disability Rates Continue Steady Climb According to CDAs 2008 Disability Claims Review 56752 3Prime Retail Launches Operation Shop Pink 56749 1Prime Retail Launches Operation Shop Pink 56749 2Champions Biotechnology and PinnacleCare Enter Into Personalized Oncology Collaboration Agreement 13976 1Champions Biotechnology and PinnacleCare Enter Into Personalized Oncology Collaboration Agreement 13976 2Champions Biotechnology and PinnacleCare Enter Into Personalized Oncology Collaboration Agreement 13976 3Champions Biotechnology and PinnacleCare Enter Into Personalized Oncology Collaboration Agreement 13976 4
...Reported Safety & Tolerability Profile,in Subj... CHICAGO, June 25, 2007 /PRNewswire-FirstCall/ -- ...eeting of the American Diabetes,Association demons...l-peptidase-4 (DPP-4) in development by Bristol-My...n with metformin,exhibited a statistically signif...
...NYVALE, Calif., June 27, 2007,/PRNewswire-FirstCal...ary results from two open-label, multi-center Phas...f Xcytrin(R),(motexafin gadolinium) Injection, the...with Alimta(R) (pemetrexed) and in,combination wit...nt,for patients with non-small cell lung cancer (N...
Other Medicine Technology:Data Demonstrated Saxagliptin Added to Metformin Improved Glycemic,Control in Subjects with Type 2 Diabetes Compared to Metformin,Alone 2Data Demonstrated Saxagliptin Added to Metformin Improved Glycemic,Control in Subjects with Type 2 Diabetes Compared to Metformin,Alone 3Data Demonstrated Saxagliptin Added to Metformin Improved Glycemic,Control in Subjects with Type 2 Diabetes Compared to Metformin,Alone 4Data Demonstrated Saxagliptin Added to Metformin Improved Glycemic,Control in Subjects with Type 2 Diabetes Compared to Metformin,Alone 5Data Demonstrated Saxagliptin Added to Metformin Improved Glycemic,Control in Subjects with Type 2 Diabetes Compared to Metformin,Alone 6Pharmacyclics Announces Interim Results From Two Ongoing Phase 2,Trials Supporting Potential of Xcytrin Plus Chemotherapy to Treat,Recurrent Non-Small Cell Lung Cancer 2Pharmacyclics Announces Interim Results From Two Ongoing Phase 2,Trials Supporting Potential of Xcytrin Plus Chemotherapy to Treat,Recurrent Non-Small Cell Lung Cancer 3Pharmacyclics Announces Interim Results From Two Ongoing Phase 2,Trials Supporting Potential of Xcytrin Plus Chemotherapy to Treat,Recurrent Non-Small Cell Lung Cancer 4Pharmacyclics Announces Interim Results From Two Ongoing Phase 2,Trials Supporting Potential of Xcytrin Plus Chemotherapy to Treat,Recurrent Non-Small Cell Lung Cancer 5
(Date:11/30/2009)...RNewswire/ -- HealthPlus of Michigan today announc... plans designed for Medicare-eligible people looki...ccess to quality health care. ,, HealthPlus Me... in Michigan, according to the "America,s Best Hea... & World Report and the National Committee on ...
(Date:11/30/2009)...or Alonzo L. Fulgham ,, WASHINGTON, Nov. 30 /P...al community once again recognizes World AIDS Day ...ldwide. This is also a time to renew our commitme... and pay homage to the millions of people who have...er in the U.S. President,s Emergency Plan for AIDS...
(Date:11/30/2009)...ewswire/ -- Major League Baseball,s Mark Teahen,... and recently acquired by the Chicago White Sox, w...d is given annually to a Major League Baseball pla...dication of baseball great Fred Hutchinson, both o...ands, Calif., native made his MLB debut with the R...
(Date:11/30/2009)...ent for blood-borne diseases, researchers say , ... medical students get stuck by needles, putting th...n fail to alert hospital authorities, which increa.... , The researchers interviewed 699 surgery res... 59 percent -- had experienced needlestick injurie...
(Date:11/30/2009)...RNewswire-USNewswire/ -- SEIU Local 21LA members a... Sodexo will hold a rally Tuesday, Dec. 1, 2009, a...arters, 3800 Desire Parkway, New Orleans, to prote...iplinary policies that target employees who are il...dexo employees who clean schools in the Recovery S...
Breaking Medicine News(10 mins):Health News:HealthPlus Launches New Medicare Advantage Plans 2Health News:HealthPlus Launches New Medicare Advantage Plans 3Health News:USAID Recognizes World AIDS Day 2Health News:Mark Teahen Named 2009 Hutch Award Winner 2Health News:Med Students Often Fail to Report Needlestick Injuries 2Health News:As H1NI Hits New Orleans in Force: School Custodians to Hold Rally to Call on Contractor to Stop Penalizing Workers Coping With Illness 2
...hat doing household activities like cleaning the h...prevent hypertension and conditions of prehyperten...rdless of intensity, four hours of accumulated dai... from prehypertensive to normal -- for an average ...
...Electric (GE), Tuesday launched HF Advantage, the ...nd made in India for the domestic and internationa...technology, the state-of-the-art product is equipp...rs at the John F. Welch Technology Centre of GE in...
...a new cheaper tissue culture vaccine for Japanese ...reported 200 deaths and 700 patients with infectio...y year due to the endemic infection of Encephaliti...4 hours, in which 12 persons died. The health ...
... of Wisconsin-Madison had reported that specific b...re affected by stress, like asthma. The study...oceedings of the National Academy of Sciences, // ...ggest potential future targets for the development...
...i may soon become part of the Indian government's ...to spread awareness about HIV/AIDS and promote the...rts have failed in reaching supplies of condoms, t... country. It has been proposed to advertise...
...ovarian cancer, according to a new Danish study, w...sk of some other forms of cancer. Women who ex...uction in the risk of development of ovarian cance...ercise habits of nearly 28,000 men and women, has ...
Other Medicine News:Health News:New X-ray machine launched by GE Healthcare 2
...x® Thermovent® T helps provide protection ... It is small and extremely lightweight making it i...With a high rate of heat and moisture recovery, it...ention., ,All HMEs and filters have ISO standard ...
circuitGuard™
Clear-Guard II™ with Port and Flextube
Clear-Guard II™
Medicine Products: